share_log

HC Wainwright & Co. Maintains Buy on Zevra Therapeutics, Raises Price Target to $15

HC Wainwright & Co. Maintains Buy on Zevra Therapeutics, Raises Price Target to $15

HC Wainwright & Co.维持对Zevra Therapeutics的买入,将目标股价上调至15美元
Benzinga ·  2023/12/28 06:13

HC Wainwright & Co. analyst Oren Livnat maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $10 to $15.

HC Wainwright & Co. 分析师奥伦·利夫纳特维持Zevra Therapeutics(纳斯达克股票代码:ZVRA)的买入并将目标股价从10美元上调至15美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发